Study finds, Cognitive Outcomes Following Intravitreal Bevac
A Study was conducted to determine the long-term cognitive outcomes in children who underwent intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP).

This single-center study enrolled 186 children between 3 and 6 years of age and included 101 children in the final analysis: premature without ROP (group 1), ROP not needing treatment (group 2), IVB monotherapy (group 3), IVB plus laser therapy (group 4), and laser monotherapy (group 5). The full-scale intelligence quotient (FSIQ) was evaluated by the Wechsler Preschool and Primary Scale of Intelligence Test at baseline and then annually for 1–2 years and compared among groups.

--The age at cognitive evaluation was 4.5–4.9 years at baseline and 6.1–7.0 years at the last follow-up.

--The FSIQ was comparable among the groups at both time points.

--Severe cognitive impairment was more common in group 4 at baseline (4%, 22%, 13%, 33%, 0% in groups 1–5, respectively) but did not differ among the groups at the last follow-up (6%, 0%, 4%, 22%, 0%).

--After adjusting for sex, Apgar score, neonatal adverse events, and days on mechanical ventilation, IVB was not associated with FSIQ either at baseline or at the last follow-up.

In conclusion, children who received IVB monotherapy were similar to other premature children with IVB monotherapy at 4.5 to above 6 years of age. At 4.5 years of age, children with IVB plus laser experienced a greater degree of cognitive impairment.